Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Wed, 25.02.2026
Wolford AG
The Supervisory Board of Wolford AG has resolved to appoint Marco Pozzo as Chief Executive Officer (CEO) and Chairman of the Management Board of Wolford AG, effective 1 March 2026.
Marco Pozzo has already been a member of the Management Board of Wolford AG since 7 July 2025 and has previously served as Deputy CEO. His three-year term on the Managem [ … ]
Wed, 25.02.2026
Polaroid Therapeutics
Introducing Antimicrobial Polymer Technology (APT™) in POLTX_Fiber™, a Class IIb advanced wound care dressing that does not contribute to antimicrobial resistance: offering improved wound management through the prevention of bacterial colonization within the dressing.ZURICH, Feb. 25, 2026 /PRNewswire/ -- Polaroid Therapeutics (PTx) today announces [ … ]
Wed, 25.02.2026
METLEN Energy & Metals
ATHENS, Greece and LONDON, Feb. 25, 2026 /PRNewswire/ -- Shell and METLEN, signed on Tuesday, February 24, 2026, a Memorandum of Understanding (MoU), establishing a framework for cooperation in the supply and trading of Liquefied Natural Gas (LNG).
Shell, one of the world's largest LNG producers and traders, and METLEN, which holds a leading posit [ … ]
Wed, 25.02.2026
Goldinvest Consulting GmbH
Canadian gold explorer Gold Hunter Resources (CSE: HUNT | WKN: A2QPAL) is applying its district consolidation concept to one of Canada's most promising gold regions. As part of its “HUNT 2.0” strategy, Gold Hunter has assembled and controls entire geological corridors rather than pursuing individual projects in isolation.
This realignment is not a [ … ]
Wed, 25.02.2026
Pentixapharm Holding AG
Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
U.S. Investigational New Drug (IND) applications for radiotheranostic pair PentixaFor and PentixaTher became active following completion of the FDA 30-day review period.
Proposed phase I/II trial designed to confirm the suitab [ … ]
Wed, 25.02.2026
Dexus Finance Pty Limited
Dexus (ASX: DXS)
ASX release
25 February 2026
Appendix 3Y
Dexus today announced an Appendix 3Y – Change of Director’s Interest Notice for Varya Davidson.
The ASX releases are available to download at www.dexus.com/dxs.
Authorised by Brett Cameron, General Counsel and Company Secretary of Dexus Funds Management Limited
For further information [ … ]
Wed, 25.02.2026
BRAIN Biotech AG
BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
Aurase shows dual action on chronic wound debridement and healing
SolasCure preparing fund raising for clinical phase 2b/3
Sequential growth forecaste [ … ]
Wed, 25.02.2026
EVN AG
Highlights
Business development in the first quarter in line with expectations
Colder weather but generation coefficients for wind and water below the long-term average
Price- and volume-related earnings decline
Positive development in the Network and South East Europe Segment thanks to investment-related organic growth
Increase in wind power [ … ]
Wed, 25.02.2026
E.ON SE
E.ON continues growth path in 2025 and delivers on energy transition
Growth strategy continued: Adjusted Group EBITDA of €9.8 billion and adjusted Group net income of €3.0 billion
Investments further increased: Total investments of €8.5 billion, including €7.0 billion in Energy Networks
Medium-term growth trajectory: Adjusted Group EBITDA to inc [ … ]
Wed, 25.02.2026
Sandoz Group AG
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Basel, February 25, 2026 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today presents its financial results for the full year and net sales for the fourth quarter of 2025.
FINANCIAL RESULTS
FY 2025
FY 2024
[ … ]
